<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440920</url>
  </required_header>
  <id_info>
    <org_study_id>311-10-001</org_study_id>
    <secondary_id>JapicCTI-111623</secondary_id>
    <nct_id>NCT01440920</nct_id>
  </id_info>
  <brief_title>A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients</brief_title>
  <official_title>A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with
      acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who
      completed a standard consolidation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence based on the Response Evaluation Criteria by the International Working Group</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-501</intervention_name>
    <description>subcutaneously administered once a week, 4 times at the dose of 0.3 mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-501</intervention_name>
    <description>subcutaneously administered once a week, 4 times at the dose of 1 mg</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-501</intervention_name>
    <description>subcutaneously administered once a week, 4 times at the dose of 3 mg</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients with acute myeloid leukemia including patients with secondary leukemia.
             However, the patients with MDS apparently evolved itno AML and patients with AML
             accompanied by t(15;17)(q22;q12),(PML/RARalpha) , should be excluded.

          -  Patients who achieved the first complete remission after the induction regimen and
             finished a standard consolidation therapy.

          -  Age: â‰¥ 60years of age(at the time of signature of the informed consent form)

          -  Sex: Male and Female

          -  Patients who are capable of giving informed consent

          -  Patient's blasts cells show expression of WT1mRNA, detected by quantitative RT-PCR.

          -  Patients must be one of the following HLA DRB1 types: HLA-DRB1*01:01, *04:05, *15:01,
             *15:02, *08:03 and *09:01.

        Key Exclusion Criteria:

          -  Patients who are scheduled for a bone marrow transplantation

          -  Patients who were administered exceeded acceptable therapeutic dose of
             immunosuppressants and adrenal cortical steroids.

          -  Patients with uncontrollable active infectious diseases

          -  Patients with autoimmune diseases (including Hashimoto's disease, idiopathic
             thrombocytopenic purpura, and autoimmune hepatitis) or with a medical history of
             active autoimmune diseases

          -  Immunocompetent patients

          -  Patients with a complication of interstitial pneumonia or with a medical history of
             interstitial pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2011</study_first_posted>
  <last_update_submitted>November 10, 2013</last_update_submitted>
  <last_update_submitted_qc>November 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>WT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

